Available online at www.sciencedirect.com

SCIENCE DIRECT

Gynecologic Oncology 95 (2004) 127–132

Gynecologic Oncology

www.elsevier.com/locate/ygyno

Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study

Naohiko Umesaki[a,*], Tuneo Fujii[b], Ryuichiro Nishimura[c], Tetsuji Tanaka[a], Masato Nishida[d], Hiroshi Fushiki[e], Ken Takizawa[f], Kaichiro Yamamoto[g], Kazuo Hasegawa[h], Rikuichi Izumi[i]
for the Japan Gynecologic Oncology Group

[a]*Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan*
[b]*Department of Obstetrics and Gynecology, National Kure Hospital, Kure, Japan*
[c]*Department of Gynecology, Hyogo Medical Center for Adults, Akashi, Japan*
[d]*Department of Obstetrics and Gynecology, National Kasumigaura Hospital, Ibaragi, Japan*
[e]*Department of Obstetrics and Gynecology, Tonami General Hospital, Tonami, Japan*
[f]*Department of Obstetrics and Gynecology, Mitsui Memorial Hospital, Tokyo, Japan*
[g]*Department of Obstetrics and Gynecology, Kinki University Medical School, Sakai, Japan*
[h]*Department of Obstetrics and Gynecology, Kakogawa Hospital, Kakogawa, Japan*
[i]*Department of Obstetrics and Gynecology, Toyamma Medical and Pharmaceutical University, Toyama, Japan*

Received 15 December 2003
Available online 28 August 2004

Abstract

Objectives. The efficacy and toxicity of combined therapy with irinotecan (CPT-11) plus mitomycin-C (MMC) were evaluated in patients with advanced or recurrent squamous cell carcinoma (SCC) of the uterine cervix.

Methods. CPT-11 (100 mg/m^2) was administered on days 1, 8, and 15 by intravenous (iv) infusion over 90 min, while MMC (10 mg/m^2 iv) was given on day 1. This regimen was repeated every 28 days and at least two courses were given.

Results. Among 51 eligible patients (median age: 52 years; range: 25–72 years), 2 showed complete response (CR) and 24 showed PR, for an overall response rate (ORR) of 51.0% (95% confidence interval: 36.6–65.3%). In patients without prior chemotherapy, the ORR was 54.8% (38.7–70.2%). Twenty-five patients (Ib2:3, IIb:17, and IIIb:5) received this regimen as neoadjuvant chemotherapy and their ORR was 76% (54.9–90.6%). Twenty-two patients were able to undergo radical surgery after NAC. The major toxicity was neutropenia, which was grade 3–4 in 59% of the patients. Grade 3–4 thrombocytopenia and anemia were also seen in 26% of the patients each. The most common nonhematologic toxicity was diarrhea (grade 3–4 in 12%).

Conclusion. CPT-11 combined with MMC can be effective against advanced or recurrent SCC of the uterine cervix.

Keywords: Chemotherapy; Cervical carcinoma; CPT-11; MMC

Introduction

After the introduction of screening using Papanicolaou smears, the incidence of invasive cervical cancer decreased and it now only holds third place among gynecologic malignancies. Although the mortality rate from cervical cancer has also been decreasing, the 5-year survival rate of

* Corresponding author. Department of Obstetrics and Gynecology, Wakayama Medical University, 811-1, Kimiidera, Wakayama 641-0012, Japan. Fax +81 73 441 0630.
E-mail address: umesaki@wakayama-med.ac.jp (N. Umesaki).

0090-8258/$ - see front matter © 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygyno.2004.06.044

patients with advanced or recurrent cancer has not improved worldwide over the last two decades [1], probably because treatment has not changed significantly.

Recent improvements in chemotherapy may lead to longer survival by combining chemotherapy agents with radiation or surgery.

After the effectiveness of cisplatin for cervical carcinoma was demonstrated, combination therapy based on cisplatin was introduced. Such regimens have achieved response rates of 16–67%, but the complete response (CR) rate is less than 20% [2–4]. Bleomycin (BLM) is often used in combination therapy and the BOMP [5] regimen or BIP [6] regimen is well known to be effective for cervical cancer. However, BLM often causes serious side effects such as pneumonitis. Therefore, a new regimen containing cisplatin without BLM would be desirable.

Irinotecan hydrochloride (CPT-11) has also demonstrated potent antitumor activity against cervical carcinoma [7]. Therefore, we tested combination chemotherapy with cisplatin plus CPT-11 and found that the response rate to this regimen was 59% for advanced or recurrent disease [8] and 78% when it was used as NAC [9].

Because advanced or recurrent cervical cancer is often complicated by ureteral stenosis or obstruction, it can be difficult to use cisplatin, suggesting that a new regimen without cisplatin should be developed. On the basis of in vitro and in vivo studies, mitomycin-C (MMC) was selected as a drug to use with CPT-11 [10].

MMC has already been used to treat cervical carcinoma [11,12], so the efficacy of CPT-11 combined with MMC can be expected. Improvement of the QOL was also predicted because the regimen would not cause symptoms such as nausea or vomiting related to cisplatin.

Accordingly, we conducted a prospective clinical trial to evaluate the therapeutic activity and toxicity of CPT-11 plus MMC as chemotherapy for advanced or recurrent cervical cancer.

Patients and methods

Patient selection

Patients had to fulfill the following eligibility criteria: histologically proven cervical cancer of stage Ib, IIb, III, or IV, or recurrent disease, as well as at least one measurable tumor documented radiographically. In all patients, primary radiotherapy and chemotherapy were completed more than 1 month earlier. Other eligibility criteria were as follows: age ≤75 years, performance status (WHO) ≤2, adequate bone marrow reserve (leucocyte count of 4.0–12.0 × 10^3/μl, platelet count ≥100 × 10^3/μl, and hemoglobin ≥9.0 g/dl), and adequate renal and hepatic function (serum creatinine ≤2 mg/dl, BUN ≤30 mg/dl, and AST/ALT ≤2× the upper limit of normal). All subjects gave written informed consent to the study.

Patients were excluded for any of the following reasons: metachronous or synchronous other cancer, concurrent infection; preexisting diarrhea, ileus, or bowel obstruction; interstitial pneumonia or pulmonary fibrosis; massive ascites; pleural effusion; uncontrolled diabetes; or a history of severe drug hypersensitivity.

Regimen

An intravenous (iv) infusion of CPT-11 (100 mg/m^2 over 90 min) was given on days 1, 8, and 15. After completion of CPT-11 infusion on day 1, MMC (10 mg/m^2) was administered as an intravenous bolus. Granulocyte colony-stimulating factor (G-CSF) was administered if grade 3 neutropenia occurred with fever ≥38.0°C or if grade 4 neutropenia developed with or without fever. This treatment schedule was repeated every 4 weeks for two or three cycles.

Doses and the treatment schedule were modified to avoid severe side effects. CPT-11 was not given on day 8 or 15 if the leucocyte count or platelet count was <3.0 × 10^3/μl or <100 × 10^3/μl, respectively. Treatment was also withheld if the patient developed diarrhea ≥grade 1 according to the Eastern Cooperative Oncology Group scale [13]. Before the next course was started, the leucocyte count had to be ≥4.0 × 10^3/μl and the platelet count ≥100 × 10^3/μl. In addition, there had to be no diarrhea, and both liver and renal function had to meet the initial eligibility criteria. Dose modification was not done for low blood cell counts or diarrhea during the same course. Additionally, if the leucocyte count was <1.0 × 10^3/μl, the platelet was <50 × 10^3/μl, or diarrhea was ≥grade 2 during any course, the dose of CPT-11 was reduced to 80 mg/m^2 for the next course.

This trial was approved by the review board of the Japanese Gynecologic Oncology Group and by the institutional review board of each participating hospital.

Evaluation of response

The criteria for assessment of tumor response were as follows: complete response (CR) was defined as the complete disappearance of all known disease for a minimum of 4 weeks; partial response (PR) was defined as a ≥50% reduction in the sum of the length × width product of all measurable lesions for a minimum of 4 weeks; progressive disease (PD) was defined as a ≥25% increase in the sum of the products of all measurable lesions, reappearance of any lesion that had disappeared, or appearance of any new lesions; and stable disease (SD) was any outcome that did not qualify as response or progression.

Patients were considered to be evaluable for toxicity if they received at least one full course of per protocol therapy. Toxicity was evaluated according to WHO criteria [14], except that diarrhea was assessed by the Eastern Cooperative Oncology scale [13].

Statistical methods

The response rate and its 95% confidence intervals (95% CI) were calculated using a binomial distribution [15].

Results

Between August 1997 and March 2002, 63 women entered this trial under the supervision of the Japanese Gynecologic Oncology Group. Ten patients were ineligible for the following reasons: four patients had a low WBC count, three patients had no measurable disease, two patients had an inadequate drug-free period, and one patient had an adrenal tumor. Among the 53 eligible patients, two patients were not evaluated for response because one patient refused to actually undergo treatment after enrollment and because of a protocol error in one patient.

Table 1 shows the characteristics of the eligible patients.

They received a median of two courses of therapy (range: 1–5 courses) and the median age was 52 years (range: 25–72 years). Sixteen patients had recurrent disease (31.4%) and 35 patients (66.7%) had advanced primary disease. Thirty-four patients (55.8%) had not received previous treatment, while 17 patients (35.3%) had already undergone treatment. Among these 17 patients, chemotherapy had been given to nine patients (17.6%) and radiotherapy had been performed in eight patients (15.7%).

Table 1
Characteristics of eligible patients

Characteristics	No. of patients	(%)
Overall	51	(100)
Age (years)		
Median	52	
Range	25–72	
Performance status		
0	42	(82.4)
1	6	(11.8)
2	3	(5.9)
Primary or recurrent		
Primary	35	(68.6)
Recurrent	16	(31.4)
Prior therapy		
No	34	(66.7)
Yes	17	(33.3)
Chemotherapy	9	(17.6)
Radiotherapy	8	(15.7)
Site of disease		
Pelvic	43	(84.3)
Cervical	34	(66.7)
Others	11	(21.6)
Metastatic site	13	(25.5)
Lymph nodes	8	(15.7)
Lung	5	(9.8)
Liver	2	(3.9)

Response to therapy

There were 2 CRs and 24 PRs, for an overall response rate (ORR) of 51.0% (95% CI: 36.6–65.3%). Eighteen patients showed SD and three had PD. The remaining four patients could not be evaluated. Table 2 shows the responses stratified according to various clinical characteristics. In patients with primary cancer, the overall response rate was 62.9% (95% CI: 44.9–78.5). In patients with recurrent disease, on the other hand, the overall response rate was only 25% (95% CI: 7.3–52.4). For patients without prior therapy (chemotherapy or radiation therapy), the overall response rate was 58.8% (95% CI: 40.7–75.4), while the overall response rate was only 35.3% (95% CI: 14.2–61.7) for patients with prior therapy. In patients without prior chemotherapy, overall responses rate was 54.8% (95% CI: 38.7–70.2). In patients with prior chemotherapy, overall responses rate was 33.3% (95% CI: 7.5–70.1).

When measurable sites were analyzed, the following response rates were observed: primary site, 23/43 cases (53.5%); lymph nodes, 4/8 cases (50%); lung 1/5 cases (20%), and liver, 1/2 cases (50%).

Twenty-five patients (stage Ib2, 3; IIb, 17; and IIIb, 5) received neoadjuvant chemotherapy with this regimen. Among the 25 patients, there was 1 CR and 18 PRs, for an overall response rate of 76% (95% CI: 54.9–90.6%). Six patients had SD and no PD was observed. Radical surgery was performed after NAC in 22 of the patients. One patient with stage IIb disease and PR after NAC received radiotherapy because consent for surgery was not obtained. One patient with stage IIIb disease and CR after NAC also underwent radiotherapy. Surgery was done for 22 of the other 23 patients.

Among the 51 patients, 23 died of cancer-related death and the median overall survival time was 21.7+ months (range: 3.4–68.4+ months). Among patients with recurrent and stage IVB disease, 18 died of cancer-related death, with a median overall survival time of 8.6 months (range: 3.4–28.2 months).

Toxicity

Table 3 lists the significant toxicities encountered during study. Leukopenia and neutropenia were the major dose-limiting toxicities. Grade 3 or worse anemia was noted in 13 patients (25.5%) and grade 3 or worse thrombocytopenia was also seen in 13 patients (25.5%). Twenty-nine patients (56.9%) developed at least grade 1 diarrhea during treatment and 16 patients (31.4%) had grade 2 or worse diarrhea. Grade 3 or 4 diarrhea occurred in six patients (11.8%). Grade 3 anorexia and alopecia were observed in five patients (9.8%) each, but grade 3 nausea and vomiting only occurred in two patients (3.9%). In the first course, 28 patients (54.9%)

Table 2
Response to the irinotecan/mitomycin C treatment

Overall	No. of patients	CR	PR	NC	PD	NE	Response rate (%)
	51	2	24	18	3	4	51.0
Performance status							
0	42	2	20	14	2	4	52.4
1	6		2	4			33.3
2	3		2		1		66.7
Primary or recurrent							
Primary	35	1	21	8	1	4	62.9
Stage Ib	4		3	1			75
Stage II	19		12	5		2	63.2
Stage III	8	1	5	1		1	75
Stage IV	4		1	1	1	1	25
Recurrent	16	1	3	10	2		25
Prior therapy							
No	34	1	19	9	1	4	58.8
Yes	17	1	5	9	2		35.3
Chemotherapy							
No	42	2	21	13	2	4	54.8
Yes	9		3	5	1		33.3
Radiotherapy							
No	36	1	20	10	1	4	58.3
Yes	15	1	4	8	2		33.3
Site of disease							
Primary site	43	1	22	14	2	4	53.5
Cervical	34	1	18	10	1	4	
Others	9		5	7	1	2	
Metastatic site	13	1	5	4	3		46.2

received the full scheduled dosage of CPT-11 (three doses per course), and CPT-11 was omitted in 19.6% on day 8 and in 39.2% on day 15. The main reason for omission of CPT-11 was leukopenia. As a result, the actual dose intensity of CPT-11 was 53.8 mg/m^2 per week versus the protocol dose intensity of 75.0 mg/m^2 per week.

There were no deaths attributable to toxicity.

Discussion

Irinotecan hydrochloride (CPT-11) is a derivative of camptothecin with potent antitumor activity. The antitumor effect of CPT-11 is related to the inhibition of DNA topoisomerase I, which is a novel mechanism different from those of other anticancer agents. CPT-11 shows strong activity against various experimental tumors and there is little cross-resistance with other antitumor agents. Clinical trials have shown that CPT-11 is active against various cancers, including cervical cancer.

We searched for an agent other than cisplatin to use in combination with CPT-11 [10]. We selected effective agents against cervical cancer by an in vitro assay using three epidermoid cell lines (keratinizing, large cell non-keratinizing, and small cell non-keratinizing types of cervical cancer). We also confirmed the effectiveness of the chemotherapy agents by a test using xenografted tumors in nude mice. These studies revealed that MMC plus cisplatin was the most effective combination followed by BLM plus cisplatin, CPT-11 plus cisplatin, and CPT-11 plus MMC. The most effective agent other than cisplatin for combination with CPT-11 was MMC. Kano et al. [16] reported that CPT-11 had a marginal supra-additive effect when combined with MMC, and they recommended the simultaneous administration of CPT-11 and MMC for clinical application in treating gynecologic malignancies. MMC inhibits the

Table 3
Toxicities of the irinotecan/mitomycin C treatment

Toxicity	No. of patients	Grade					Total	%	Grade 3–4	%
		0	1	2	3	4				
Hematologic										
Leukopenia	51	4	5	14	20	8	47	(92)	28	(55)
Neutropenia	51	13		8	19	11	38	(75)	30	(59)
Anaemia	51	8	6	24	13		43	(84)	13	(26)
Thrombocytopenia	51	27	6	5	7	6	24	(47)	13	(26)
Gastrointestinal										
Diarrhea	51	22	13	10	5	1	29	(57)	6	(12)
Nausea or vomiting	51	10	20	20	2		42	(82)	2	(4)
Anorexia	51	13	17	16	5		38	(75)	5	(10)
Others										
Alopecia	51	19	17	10	5		32	(63)	5	(10)
Hepatic function disorder	51	49	1	1			2	(4)		
AST (GOT)	51	50			1		1	(2)	1	(2)
AST (GPT)	51	50			1		1	(2)	1	(2)
ALP	51	50		1			1	(2)		
Paralysis intestinal	51	50	1				1	(2)		
Abdominal pain	51	50	1				1	(2)		
Infection	51	50	1				1	(2)		
Rash	51	49			2		2	(4)	2	(4)

cleavage of DNA, so synergism between CPT-11 and MMC may occur because alkylating agents could make some CPT-11-induced DNA damage irreparable.

Villalona-Calero and Kolesar [17] reported that MMC was a modulator of CPT-11 activity because it increased topoisomerase I expression.

MMC was reported to achieve a response rate of 22% for cervical cancer [18] and has been used to treat cervical cancer in combination with many agents. BM [12] and BOMP [5] were well-known chemotherapy regimens for cervical cancer. These facts suggested that MMC plus CPT-11 could be a useful new chemotherapy regimen.

The schedule and the dose of CPT-11 and MMC were based on previous reports. CPT-11 was administered on days 1, 8, and 15 according to the regimen for a phase II study [7]. MMC was administered on day 1 because this was the day of cisplatin administration in the combined CPT-11 and cisplatin regimen. MMC shows dose-dependent activity, so it was administered by bolus injection [19]. The doses of CPT-11 and MMC were determined according to other reports [20,21].

Previously, CPT-11 plus MMC has been used for ovarian carcinoma. Shimizu et al. [20] reported that CPT-11 was administered at a dose of 120 mg/m^2 intravenously (iv) on days 1 and 15, while MMC was given intravenously at a dose of 7 mg/m^2 on days 1 and 15. This regimen was found to be effective for platinum-refractory clear cell or mucinous cyst adenocarcinoma of the ovary and toxicity was acceptable (including manageable hematologic reactions, diarrhea, nausea or vomiting, and alopecia).

Takizawa et al. [21] demonstrated that 100 mg/m^2 of CPT-11 and 5 mg/m^2 of MMC at 2-week intervals were reasonably well tolerated, while Villalona-Calero and Kolesar [17] used MMC (6 mg/m^2 on day 1) plus CPT-11 (125 mg/m^2 on days 2 and 8) to treat breast or esophageal (cardiac) adenocarcinoma. Based on these reports, we selected three doses of CPT-11 (100 mg/m^2) at 1-week intervals plus MMC (10 mg/m^2 on day 1).

In our regimen, the dose intensity of CPT-11 was 75 mg/m^2 per week and that of MMC was 2.5 mg/m^2 per week. Although our regimen had a higher dose intensity compared with these other reports, the actual CPT-11 dose intensity delivered to the patients was 58 mg/m^2 per week. This dose intensity of CPT-11 was similar to that for the regimen of Shimizu et al.

The response rate was 51% for advanced or recurrent cervical cancer. Several combination chemotherapy regimens have been tested in phase II studies [6,22–24] and objective responses have been documented in 30–70% of patients. However, it is difficult to compare the results of these studies because of the relatively small number of subjects and biases of patient selection. We previously performed a phase II study of CPT-11 and cisplatin as first-line chemotherapy for advanced or recurrent cervical cancer [8]. The eligibility criteria and clinical characteristics of the patients were similar to those of this study, so we were able to compare the response to CPT-11 plus cisplatin with that to CPT-11 plus MMC. As a result, we found no difference between these two regimens and CPT-11 plus MMC showed moderate activity against cervical cancer.

In recent years, neoadjuvant chemotherapy has been extensively investigated in patients in patients with cervical cancer. Of the 51 patients entered in this study, 25 patients (49%) were registered as having neoadjuvant chemotherapy. The response rate was 76% (19/25), which is similar to previous reports [9].

The most frequent grade 3–4 toxicities were neutropenia and thrombocytopenia. The frequency of neutropenia was lower than with other regimens, such as CPT-11 + CDDP [8], CDDP + IFM [25], or CDDP + IFM + BLM [25]. On the other hand, thrombocytopenia was more frequent. One possible explanation for this finding is that the pattern of hematological toxicity differs between CPT-11 and MMC, with neutropenia being typical of the former and thrombocytopenia being typical of the latter [26]. G-CSF is effective for elevating the neutrophil count, but there is no treatment for thrombocytopenia except platelet transfusion. Therefore, thrombocytopenia is a problematic toxicity of this regimen. Fortunately, platelet transfusion was not needed in this study, but reduction of the MMC dose for the next course needs to be considered if grade 3–4 thrombocytopenia occurs. Diarrhea is the most important nonhematologic toxicity of CPT-11. The frequency of grade 3–4 diarrhea was reported to be 19.2% in a late phase II study of CPT-11 [7]. The same dose of CPT-11 was used in the present trial and MMC was added, but grade 3–4 diarrhea only occurred in 12%. A lower frequency of diarrhea was achieved in this study because many of the subjects were previously untreated and because we became more familiar with the toxicities of CPT-11.Although the frequency of diarrhea was reduced, it still caused impairment of QOL. Therefore, diarrhea needs to be managed carefully. Recently, hangeshashintou [27,28] and loperamide [29] were found to be useful for preventing diarrhea induced by CPT-11 therapy, so these medicines should be used more actively.

In summary, CPT-11 plus MMC showed moderate activity against cervical cancer. Furthermore, this regimen does not need hydration and nausea or vomiting is rare, so the QOL is also well.

In conclusion, CPT-11 plus MMC showed a useful regimen for advanced and recurrent cervical cancer.

References

[1] Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 2002;20:179–88.

[2] Alberts DS, Garcia D, Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol 1998;18:11–24.

[3] Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol 1995;22:67–72.
[4] Thigpen T, Vance RB, Khansur T, Malamud F. The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol 1997;24:41–6.
[5] Alberts DS, Kronmal R, Baker LH, Stock-Novack DL, Surwit EA, Boutselis JG, et al. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study. J Clin Oncol 1987;11:1791–5.
[6] Buxton EJ, Meanwell CA, Hilton C, Mould JJ, Spooner D, Chetiyawardana A, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 1989;81:359–61.
[7] Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers (in Japanese). Gan To Kagaku Ryoho 1991;18:1681–9.
[8] Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, et al. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 2000;58:31–7.
[9] Sugiyama T, Nishida T, Kumagai S, Nishio S, Fujiyoshi K, Okura N, et al. Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer 1999;81:95–8.
[10] Fushiki H, Hidaka T, Hori S, Fujimura M, Yamakawa Y, Izumi R. Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice (in Japanese). Gan To Kagaku Ryoho 1997;24:1981–5.
[11] Baker LH, Opipari MI, Izbicki RM. Phase II study of mitomycin-C, vincristine, and bleomycin in advanced squamous cell carcinoma of the uterine cervix. Cancer 1976;38:2222–4.
[12] Miyamoto T. A sequential combination of bleomycin and mitomycin C in the treatment of advanced squamous cancers. Recent Results Cancer Res 1978;63:179–90.
[13] Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55.
[14] WHO. Handbook for reporting results of cancer treatment. WHO Offset Publ, vol. 48. Geneva, Switzerland: World Health Organization; 1979.
[15] Simon R. Confidence intervals for reporting results of clinical trial. Ann Intern Med 1986;105:429–35.
[16] Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604–10.
[17] Villalona-Calero MA, Kolesar JM. Mitomycin as a modulator of irinotecan anticancer activity. Oncology 2002;16:21–5.
[18] Wasserman TH, Carter SK. The integration of chemotherapy into combined modality treatment of solid tumor: VIII. Cervical cancer. Cancer Treat Rev 1997;4:25–46.
[19] Hata T. Studies of mitomycin C, especially method of administration. Cancer Chemother Rep 1961;13:67–77.
[20] Shimizu Y, Umezawa S, Hasumi K. A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singap 1998;27:650–6.
[21] Takizawa K, Satow Y, Kato Y, Kawana T. Two patients with ovarian cancer refractory to cisplatin-based chemotherapy managed by a new combination chemotherapy with irinotecan hydrochloride and mitomycin-C. Int J Clin Oncol 1997;2:238–42.
[22] Murad AM, Triginelli SA, Ribalta JCL. Phase II trial of bleomycin, Ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol 1994;12:55–9.
[23] Long HJ, Cross WG, Wieand HS, Webb MJ, Mailliard JA, Kugler JW, et al. Phase II trial of methotreaxate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol 1995;57:235–9.
[24] Papadimitriou CA, Dimopoulos MA, Giannakoulis N, Sarris K, Vassilakopoulos G, Akrivos T, et al. Cancer 1997;79:2391–5.
[25] Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2002;20:1832–7.
[26] Yamao T, Shirao K, Matsumura Y, Muro K, Yamada Y, Goto M, et al. Phase I–II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Ann Oncol 2001;12:1729–35.
[27] Narita M, Nagai E, Hagiwara H, Aburada M, Yokoi T, Kamataki T. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 1993;23:5–10.
[28] Sakata Y, Suzuki H, Kamataki T. Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11). Gan To Kagaku Ryoho 1994;21:1241–4.
[29] Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994;86:446–9.

J Cancer Res Clin Oncol (2004) 130: 161–168
DOI 10.1007/s00432-003-0517-8

ORIGINAL PAPER

F. Kimura · J. Watanabe · H. Hata · T. Fujisawa
Y. Kamata · Y. Nishimura · T. Jobo · H. Kuramoto

PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus

Received: 4 June 2003 / Accepted: 9 October 2003 / Published online: 20 December 2003

Abstract *Purpose*: PTEN is a tumor suppressor gene that inhibits cell proliferation by regulating intracellular signaling pathways, and this activity can be abolished by mutations of the PTEN gene. This study was designed to examine the correlation of PTEN expression with the expression of cell cycle regulators and with clinicopathological parameters in endometrioid adenocarcinoma of the uterine corpus. *Methods*: Tissue samples of 117 endometrioid adenocarcinomas in addition to those of 19 normal endometria and 20 endometrial hyperplasias were used for the study. Immunohistochemical staining for PTEN protein was performed with the labeled streptavidin-biotin method on formalin-fixed and paraffin-embedded tissue samples. PTEN expression was represented as the staining score. *Results*: Immunohistochemistry showed that the nuclei of cells were positive for PTEN. The PTEN staining score of normal endometrium was significantly higher in the proliferative phase than in the secretory phase. The scores of various endometrial hyperplasias were not significantly different from each other, regardless of the type of hyperplasia. The PTEN staining scores of endometrioid adenocarcinomas were 7.6±5.2 in G1, 9.6±5.2 in G2, and 11.9±3.7 in G3, and increased significantly as the histological grade increased. PTEN staining score was not significantly correlated with clinicopathological parameters such as FIGO stage, myometrial invasion, lymph-vascular space invasion (LVSI), lymph node metastasis or group, but was significantly correlated with labeling indices (LIs) of cell cycle regulators such as Ki-67, cdk2, cyclin A, cyclin D1, cyclin E, p27, and p53. The PTEN staining score of p53-wild cases was significantly lower than that of p53-mutant ones, but there was no significant difference of the score in cases with different PTEN gene status. PTEN expression was significantly lower in cases with both high levels of estrogen receptor and progesterone receptor. *Conclusion*: PTEN protein expression was decreased in well-differentiated and less growth-aggressive endometrial carcinoma with wild-type p53 gene and high levels of ER and PR. This suggests that disturbed PTEN expression occurs in an early phase of the tumorigenesis of well-differentiated endometrial carcinoma.

Keywords PTEN · p53 · Estrogen receptor · Progesterone receptor · Endometrioid adenocarcinoma

F. Kimura · T. Fujisawa · Y. Kamata · Y. Nishimura
H. Kuramoto
Department of Clinical Cytology,
Graduate School of Medical Sciences,
Kitasato University, Kitasato, Kanagawa, Japan

J. Watanabe (✉)
Department of Pathology,
Kitasato University School of Medicine,
1-15-1, 228-8555 Kitasato, Sagamihara, Kanagawa, Japan
E-mail: watajun@med.kitasato-u.ac.jp
Tel.: +81-42-7789276
Fax: +81-42-7789276

H. Hata · T. Jobo
Department of Obstetrics and Gynecology,
Kitasato University School of Medicine,
Kitasato, Kanagawa, Japan

Introduction

The tumor suppressor gene PTEN (phosphatase and tensin homologue deleted on chromosome 10) is localized on chromosome 10q23. The gene product is a 55-kD protein composed of 403 amino acids. PTEN is a dual-specificity phosphatase with a sequence similar to that of the cytoskeletal protein tensin (Hinoda et al. 1998; Maehama and Dixon 2000; Parsons 1998; Tamura et al. 1999). PTEN is also frequently mutated in a wide range of human tumors such as glioblastoma (Sano et al. 1999; Steck et al. 1997) and cancers of the prostate (Girl and Ittamann 1999), breast (Perren et al. 1999), thyroid (Gimm et al. 2000), ovary (de la Cuesta et al. 1996; Obata et al. 1998) and endometrium (Ellenson 2000; Mutter et al. 2000b). Most of the mutations of the PTEN gene in tumors are localized in the phosphatase

domain, which influences the phosphatase activity (Hinoda et al. 1998; Maehama and Dixon 2000; Parsons 1998; Tamura et al. 1999). PTEN has an antagonistic effect on intracellular signaling pathways induced by integrin or growth factors, and inhibits cell proliferation and finally induces apoptosis. One of the inhibitory mechanisms is that PTEN dephosphorylates focal adhesion kinase (FAK), which plays a major role in a transcription-regulatory signaling system. FAK is activated by integrin and growth factors, and induces focal adhesion, cytoskeletal formation, and cellular spreading, invasion and migration (Mochizuki 1999; Tamura et al. 1998a, 1998b, 1999). Another mechanism is that PTEN suppresses the signaling pathway that goes through protein kinase B (Akt/PKB) by dephosphorylating phosphatidylinositol 3,4,5-trisphosphate (PIP3). It thereby leads to apoptosis and inhibits cell proliferation (Gu et al. 1998; Tamura et al. 1999). PTEN also suppresses the activity of mitogen-activated protein kinase (MAPK) by dephosphorylating Src homologous and collagen (Shc) as an adaptor protein. Furthermore, PTEN also inactivates the stimulatory effect on cell growth induced by estrogen, and it has been suggested that this effect of PTEN is abolished by mutations of the PTEN gene(Mutter et al. 2000c).

In this study, we examined PTEN expression immunohistochemically in endometrioid adenocarcinoma of the uterine corpus as well as normal endometrium and endometrial hyperplasia, and examined the correlation of PTEN expression with the expression of cell cycle regulators, and with clinicopathological parameters, estrogen, and progesterone receptor levels, and p53 gene mutation.

Materials and methods

Tissue samples

Tissue samples of 19 normal endometria (eight cases of the proliferative phase and 11 of the secretory phase), 20 endometrial hyperplasias [nine cases of simple hyperplasia (SH), four of complex hyperplasia (CH) and seven of complex atypical hyperplasia (CAH)] and 117 endometrioid adenocarcinomas, including 67 well-differentiated (G1), 24 moderately differentiated (G2), and 26 poorly differentiated (G3) adenocarcinomas, were surgically obtained with informed consent at Kitasato University Hospital between 1983 and 2000. No patients received any therapy before surgery.

Immunohistochemistry

Immunohisitochemical staining for PTEN protein was performed with the labeled streptavidin-biotin (LSAB) method (LSAB-kit, DAKO, Kyoto, Japan) on formalin-fixed and paraffin-embedded tissue samples. Tissue samples were sectioned at 3-μm thickness and deparaffinized in xylene. Endogenous peroxidase activity was inhibited with 3% hydrogen peroxide for 15 min. Antigen retrieval was performed by autoclaving at 121 °C for 15 min in 0.01 mol/l citrate buffer (pH6.0). After the sections were incubated with 10% normal swine serum for 10 min, they were incubated with mouse monoclonal anti-PTEN antibody (clone 28H6, 1:400, Novocastra, Newcastle, UK) overnight at 4 °C. The sections were washed in 0.01 mol/l phosphate-buffered saline (PBS) and incubated with biotinylated anti-mouse goat immunoglobulin for 10 min, and then with horseradish peroxidase-labeled streptavidin for 10 min. The peroxidase reaction was developed in 0.02% 3,3'-diaminobenzidine tetrahydrochloride solution containing 0.003% hydrogen peroxide. The nuclei were lightly counterstained with Mayer's hematoxylin.

PTEN expression was compared with the expression of Ki-67, cdk2, cyclin A, cyclin D1, cyclin E, p27, and p53, which were also examined immunohistochemically. The staining methods were described elsewhere (Fujisawa et al. 2001; Kato et al. 2003; Kyushima et al. 2002; Watanabe et al. 2002). In brief, the antibodies used were those for Ki-67 (rabbit polyclonal, 1:50, Dako, Kyoto, Japan), cdk2 (rabbit polyclonal, 1:2000, Santacruz, Calif., USA), cyclin A (clone 6E6, 1:100, Novocastra), cyclin D1 (clone DCS-6, 1:80, Oncogene, Mass., USA), cyclin E (clone 13A3, 1:40, Novocastra), p27 (clone 1B4, 1:200, Novocastra) and p53 (clone DO-7, 1:80, Novocastra).

Evaluation of immunohistochemical staining

The level of PTEN protein was expressed as the PTEN staining score, which was calculated using both the labeling index (LI) and staining intensity. LI was defined as the percentage of cells positive for PTEN among approximately 1,200 cells in three randomly selected high-power fields. LIs were classified into four groups: group 1 ($0\% \leq LI < 25\%$), group 2 ($25\% \leq LI < 50\%$), group 3 ($50\% \leq LI < 75\%$) and group 4 ($75\% \leq LI \leq 100\%$), and these groups were given scores of 1, 2, 3, and 4 points (LI score), respectively.

The staining intensity of the nuclei of tumor cells, which was compared with that of adjacent stromal cells taken as a control with intensity of +, was also classified into four groups with intensity judged to be −, ±, +, or + +, and these groups were scored as 1, 2, 3, and 4 points (staining intensity score), respectively.

The product of LI score times staining intensity score was used to evaluate PTEN expression as the PTEN staining score, which ranged from 1 to 16 points. The expression levels of cell cycle regulators were evaluated by calculating LI by the same method as described above (Kato et al. 2003; Kyushima et al. 2002; Watanabe et al. 2002).

p53 and PTEN gene mutation analysis

Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis was performed to analyze mutations of the p53 and PTEN genes. In brief, DNA of endometrial cancer tissues was extracted by a phenol chloroform method (Uchida et al. 1993). The oligonucleotide primer pairs located in exons 5 to 8 of the p53 gene and the PCR conditions also conformed to the methods of Uchida et al. The primer sets used for the p53 gene were as follows: Exon5(sense,antisense): 5'-TGTTCACTTGTGCCCT GACT-3', 5'-CAGCCCTGTCGTCTCTCCAG-3'; Exon6:5'-TGT TTGCCCAGGGTCCCCAG-3', 5'-GGAGGGCCACTGACAAC CA-3'; Exon7:5'-CTTACCACAGGTCTCCCCAA-3', 5'-AGGGG TCAGCGGCAAGCAGA-3'; Exon8:5'-TTGGGAGTAGATGG AGCCT-3', 5'-AGTGTTAGACTGGTAAACTTT-3'.

The oligonucleotide primer pairs located in exons 1 to 9 of the PTEN gene and the PCR conditions conformed to those used in the method of Steck et al. (Steck et al. 1997). The primer sets used for the PTEN gene were as follows: Exon1 (sense,antisense): 5'-CAGCCGTTCGGAGGATTA-3',5'-ATATGACCTAGCAAC CTGACCA-3'; Exon2:5'-TGACCACCTTTTATTACTCC-3', 5'-TACGGTAAGCCAAAAAATGA-3'; Exon3:5'-ATATTCTC TGAAAAGCTCTGG-3', 5'-TTAATCGGTTTAGGAATACAA-3'; Exon4:5'-TTCAGGCAATGTTTGTTA-3', 5'-CTTTATGCAATA CTTTTTCCTA-3'; Exon5:5'-AGTTTGTATGCAACATTTCTAA-3', 5'-TTCCAGCTTTACAGTGAATTG-3'; Exon6:5'-ATATGTTCT TAAATGGCTACG-3', 5'-AGCAACTATCTTTAAAACCTGT-3'; Exon7:5'-ACAGAATCCATATTTCGTGTA-3', 5'-TAATGTCT

CACCAATGCCA-3'; Exon8:5'-TGCAAAATGTTTAACATAG GTGA-3', 5'-GTAAGTACTAGATATTCCTTGTC-3'; Exon9:5'-AAGATGAGTCATATTTGTGGGT-3', 5'-GACACAATGTCC TATTCCAT-3'.

The 5'-end of each primer was labeled with [γ-^{32}P]ATP. SSCP was performed according to the method of Orita et al. (Orita et al. 1989). In brief, electrophoresis was performed at 40 W for 3 h on a 5% polyacrylamide gel. The gel was dried at 80 °C for 45 min and exposed to Kodak XAR film at room temperature for 15 min to 24 h with an intensifying screen. DNA extracted from lymphocytes of a normal woman whose menstrual cycle was regular was used as a normal control. Aberrant bands or mobility shift indicated gene mutations. p53 and PTEN gene analysis was performed randomly in 56 cases in the present series.

ER and PR expression analysis

Estrogen receptor (ER) and Progesterone receptor (PR) expression was analyzed with a radioreceptor assay or enzyme immunoassay at Kitasato Biochemical Laboratory (Sagamihara, Kanagawa, Japan). Expression of 5.0 fmol/mg cytosol protein was the cut-off value.

Comparison with clinicopathological parameters

Clinicopathological parameters of the patients were obtained from the tumor registry of the Department of Gynecology, Kitasato University Hospital, and compared with PTEN expression.

Statistical analysis

Statistical analysis of the correlation between the PTEN staining score and the LI of each cell cycle regulator was conducted with Spearman's rank correlation test. The Mann Whitney U-test was used to examine the correlation of the PTEN staining score with clinicopathological parameters, p53 mutation, and ER and PR levels. The correlation between PTEN gene mutation and grade was analyzed with Fisher's exact test. P-values less than 0.05 were considered statistically significant.

Fig. 1a,b **a** PTEN protein expression in the proliferative phase of normal endometrium. Almost all nuclei of glandular cells show the immunoreaction (PTEN staining score 16, ×200); **b** In the secretory phase, the glandular cells are slightly positive for PTEN in the nuclei (PTEN staining score 4, ×200)

Results

PTEN protein in the proliferative and secretory phase endometria was detected in the nuclei of endometrial columnar cells and adjacent stromal cells (Fig. 1a,b). The PTEN staining scores of columnar cells in the proliferative and secretory phases were 13.3 ± 3.5 and 9.0 ± 3.1, respectively (Table 1). The former was significantly higher than the latter.

In endometrial hyperplasias, PTEN protein expression showed the same pattern as in normal endometria (Fig. 2a–c). The PTEN staining scores of SH, CH and CAH were 10.1 ± 4.4, 12.3 ± 2.9, and 11.6 ± 1.1, respectively (Table 1), and were not significantly different from each other. The PTEN staining scores were not significantly different between normal endometria and endometrial hyperplasias.

The PTEN staining in a case of G1 adenocarcinoma was entirely negative, (Fig. 3a). In a case of G3 adenocarcinoma, almost all nuclei of the cancer cells appeared positive for PTEN (Fig. 3b). The PTEN staining scores of G1, G2, and G3 endometrioid adenocarcinomas were 7.6 ± 5.2, 9.6 ± 5.2, and 11.9 ± 3.7, respectively. The score of G1 adenocarcinomas was significantly lower than that of G3 adenocarcinomas (Table 1), and was also significantly lower than those of endometrial hyperplasia and the proliferative phase endometrium (Table 1).

PTEN staining score was positively correlated with the LIs of cell cycle regulators such as Ki-67, cdk2, cyclin A, cyclin D1, cyclin E, p27, and p53 (Table 2).

PTEN staining score was not significantly associated with clinicopathological parameters such as FIGO stage, myometrial invasion, lymph-vascular space invasion (LVSI), lymph node metastasis or group (group 1, cancer with coexisting endometrial hyperplasia; group 2, cancer with coexisting normal endometrium; group 3, only cancer; Ohkawara et al. 2000) (Table 3).

The PTEN staining scores in cases with wild-type and mutant p53 genes were 7.4 ± 5.3 and 11.9 ± 4.6, respectively, and the former was significantly lower than the latter (Table 4). In contrast, the PTEN staining scores in cases with wild-type and mutant PTEN genes were 8.8 ± 5.3 and 7.7 ± 6.0, respectively, showing no

Table 1 The correlation between PTEN staining score and normal endometrium, endometrial hyperplasia, and endometrioid adenocarcinoma of the uterine corpus

	No.of cases	PTEN staining score Mean	±	SD	P-value			
Proliferative phase	8	13.3	±	3.5	0.0208*			
Secretory phase	11	9.0	±	3.1			N.S.	
Endometrial hyperplasia, simple(SH)	9	10.1	±	4.4	N.S.			
Endometrial hyperplasia, complex(CH)	4	12.3	±	2.9		N.S.		0.0046*
					N.S.			
Atypical endometrial hyperplasia, complex(CAH)	7	11.6	±	1.1			0.0101*	
G1	67	7.6	±	5.2	N.S.	0.0004*		
G2	24	9.6	±	5.2				
G3	26	11.9	±	3.7	N.S.			

*$p < 0.05$; significant, N.S. ; not significant, Mann-Whitney U test

significant difference between them. When analyzed in relation to pathological grade, PTEN staining scores with or without p53 and PTEN gene mutation were not significantly different except these between G1 vs G2 with p53 mutation ($P=0.04$). PTEN expression was high in G2 and G3 with PTEN gene mutation, although statistical analysis could not be conducted because of the limited number of cases. PTEN expression with or without PTEN gene mutation was not significantly correlated in each grade examined by Fisher's exact test (Table 4).

The PTEN staining scores were 6.5 ± 5.3 in the cases with ER $\geq$ 50 f mol/mg protein and 9.5 ± 4.9 in cases with ER $<$ 50 f mol/mg protein, and were 6.6 ± 5.5 in cases with PR $\geq$ 100 f mol/mg protein and 9.7 ± 4.8 in cases with PR $<$ 100 f mol/mg protein. PTEN expression was significantly lower in cases with either a high level of ER or PR than in their counterparts with low receptor levels. PTEN staining scores of each grade were not significantly correlated each other in either high or low ER and PR groups. G1 with high ER ($P=0.079$) and PR ($P=0.026$) groups showed lower PTEN expression than those with low their groups (Table 5).

Discussion

The PTEN staining score was significantly higher in the proliferative endometrium than in the secretory endometrium in this study. Mutter et al. reported that all endometrial columnar and stromal cells in the proliferative phase were positive for PTEN, and that PTEN expression was decreased or absent in the secretory phase (Mutter 2000a; Mutter et al. 2000c). That result is similar to ours in this study. This indicates that PTEN protein may be induced in the proliferative phase as a negative feedback response to the stimulatory effect of estrogen on proliferation, and may be decreased in the secretory phase due to antagonism of estrogen's action by progesterone (Mutter 2000a; Mutter et al. 2000b, 2000c).

PTEN gene mutation in endometrial hyperplasia with or without atypia has been detected in 19–55% (Ellenson 2000; Maxwell et al. 1998; Mutter et al. 2000b). In contrast, in this study, the level of PTEN expression in endometrial hyperplasia as examined immunohistochemically was not different from that in proliferative phase endometrium and also showed no significant correlation with the subtype of hyperplasia. It is suggested that PTEN staining using the present antibody might not be associated with PTEN gene mutation in endometrial hyperplasia, although we have not examined the mutation.

It has been suggested that there may be two different sequences of the development of endometrioid adenocarcinoma; one develops through endometrial hyperplasias and mainly consists of well-differentiated cancer and coexists with endometrial hyperplasia (Ohtani et al. 1999; Fujimoto et al. 1998). The other is an estrogen-unrelated type that originates de novo from atrophic endometrium and develops into poorly differentiated cancer without endometrial hyperplasia, and is associated with gene mutation of p53 and c-erbB2/neu amplification (Sherman 2000; Ohtani et al. 1999; Bussaglia et al. 2000). The latter type of carcinoma occurs not infrequently in post-menopausal women and shows aggressive behavior. The former is known to be promoted by an unopposed estrogen environment (Fujimoto et al. 1998; Sherman 2000). ER is first phosphorylated after being combined with estrogen and is



Fig. 2a–c a PTEN protein expression in endometrial hyperplasia, simple type. Almost all nuclei of glandular cells show the immunoreaction (PTEN staining score 16, ×200); b PTEN protein expression in endometrial hyperplasia, complex type. Almost all nuclei of glandular cells show the immunoreaction (PTEN staining score 16, ×200); c PTEN protein expression in endometrial atypical hyperplasia, complex type. Almost all nuclei of glandular cells show the immunoreaction (PTEN staining score 12, ×200)



Fig. 3a,b a Negative PTEN protein expression in endometrioid adenocarcinoma (G1) (PTEN staining score 1, ×200); b PTEN protein expression in endometrioid adenocarcinoma (G3) (PTEN staining score 12, ×200)

Table 2 The correlation between PTEN staining score and LIs of cell cycle regulators in endometrioid adenocarcinopma of the uternine corpus (*LI* labeling index)

Cell cycle regulator	*r*	P-value
Ki-67	0.32	0.0006*
cdk2	0.21	0.0289*
Cyclin A	0.34	0.0005*
Cyclin D1	0.19	0.0428*
Cyclin E	0.24	0.0090*
p27	0.22	0.0208*
p53	0.44	0.0014*

*$P < 0.05$ significant; Spearman's rank correlation test

then activated by changing its conformation. Activated ER combines with the estrogen response element in the nucleus and induces the expression of transforming growth factor-1 (TGF-1), epithelial growth factor (EGF) receptor and cyclin D1 (Hata et al. 1998; Kato et al. 1998; Weng et al. 2001). Subsequently, it activates a PIP3-Akt pathway that causes cell growth and inhibits apoptosis. Then, by activation of the estrogen receptor through GRB2-Sos-Ras, resulting in activation of the Shc-MAPK or Raf-MAPKK-MAPK pathway, cell growth is further promoted. In normal endometrial cells, PTEN suppresses the estrogen-stimulated cell proliferation by dephosphorylating Shc, FAK, and PIP3 (Gu et al. 1998; Mochizuki 1999; Tamura et al. 1998a, 1998b,

Table 3 The correlation between PTEN staining score and clinicopathological parameters in endometrioid adenocarcinoma of the uterine corpus

Clinicopathological parameter		No.of cases	PTEN staining score Mean	±	SD		P-value
Stage	FIGO I	76	8.9	±	4.9	I vs II	N.S.
	FIGO II	12	9.7	±	6.3	I vs III	
	FIGO III	26	8.9	±	5.6	I vs IV	
	FIGO IV	3	9.3	±	4.6	I vs II, III, IV	
Myometrial invasion	< 1/3	53	9.7	±	4.8		N.S.
	1/3≦	56	8.2	±	5.5		
LVSI	−	80	8.5	±	5.3		N.S.
	+	28	9.9	±	4.6		
Lymph node metastasis	−	92	8.9	±	5.2		N.S.
	+	13	10.5	±	4.7		
Group	1	49	7.9	±	5.4	1 vs 2	N.S.
	2	50	9.2	±	4.9	1 vs 3	
	3	15	10.9	±	4.6	2 vs 3	

LVSI ; Lymph-vascular space invasion, N.S. ; not significant, Mann-Whitney U test

Table 4 The correlation between PTEN staining score, and p53 and PTEN mutation in endometrioid adenocarcinoma of the uterine corpus

Mutation		No.of cases	PTEN staining score Mean	±	SD	P-value	Grade	No.of cases	PTEN staining score Mean	±	SD	P-value
p53	−	44	7.4	±	5.3	0.0094*	G1	34	6.6	±	5.5	N.S.
							G2	6	9.2	±	4.3	
							G3	4	12.0	±	0.0	
	+	11	11.9	±	4.6		G1	4	9.8	±	4.5	0.04*
							G2	4	15.0	±	2.0	
							G3	3	10.7	±	6.1	
PTEN	−	37	8.8	±	5.3	N.S.	G1	22	7.3	±	5.5	N.S.
							G2	9	11.4	±	4.8	
							G3	6	10.7	±	3.3	
	+	19	7.7	±	6.0		G1	17	6.9	±	5.9	
							G2	1	12.0			
							G3	1	16.0			

*p < 0.05 ; significant, N.S. ; not significant, Mann-Whitney U test

1999; Weng et al. 2001). It is thought that Shc, FAK, and PIP3 cannot be dephosphorylated when the PTEN gene is mutated and cell growth cannot be inhibited. (Gu et al. 1998; Mochizuki 1999; Tamura et al. 1998a, 1998b, 1999). Mutation of PTEN has been analyzed in various advanced cancers (Steck 1997), and detected in 34-83% of endometrial adenocarcinomas (Bussaglia et al. 2000; Ellenson 2000; Kurose et al. 1998; Levine et al. 1998; Maxwell et al. 1998; Mutter 2000a). In the present study, PTEN gene mutation was seen in 19 of 56 cases (34%). Our data showed that PTEN expression was decreased in G1 more than in G3, endometrial hyperplasia and proliferative phase endometrium. There are reports that PTEN gene mutation was detected in well-differentiated carcinomas, including brain tumors (Sano et al. 1999; Steck et al. 1997), and carcinomas of the prostate (Girl and Ittamann 1999), breast (Perren et al. 1999), and thyroid (Gimm et al. 2000).

No correlation between PTEN gene mutation and PTEN protein expression was observed in our study and there was also no difference when examined depending on each histological grade. The reason for this may be that the PTEN gene is frequently mutated as a frame shift in the phosphatase domain (Hinoda et al. 1998;

Table 5 The correlation between PTEN staining score, and estrogen and progesterone receptor expression in endometrioid adenocarcinoma of the uterine corpus

	f mol/mg protein	No.of cases	PTEN staining score Mean ± SD	P-value	Grade	No.of cases	PTEN staining score Mean ± SD	P-value
ER	High(≧50)	18	6.5 ± 5.3	0.0241*	G1	17	6.2 ± 5.2	0.07
					G2	0	-	
					G3	1	12.0	
	Low(<50)	77	9.5 ± 4.9		G1	39	8.6 ± 5.0	N.S.
					G2	19	9.7 ± 5.4	
					G3	19	11.2 ± 3.8	
PR	High(≧100)	22	6.6 ± 5.5	0.0256*	G1	18	5.6 ± 4.8	0.026*
					G2	2	4.0	
					G3	2	14.0	
	Low(<100)	72	9.7 ± 4.8		G1	37	9.0 ± 5.1	N.S.
					G2	17	9.8 ± 5.2	
					G3	18	10.9 ± 3.7	

*$p < 0.05$; significant, N.S.; not significant, Mann-Whitney U test

Maehama and Dixon 2000; Parsons 1998; Tamura et al. 1999), whereas the epitope recognized by the antibody that was used in this study was located around 200 amino acids from the C-terminus. Therefore, cases of cancers with PTEN gene mutation might not have been detected by immunohistochemical staining. At least some PTEN gene mutations are not expected to be detected by this antibody.

In our study, high expression of PTEN protein was observed in G3 endometrial carcinomas, and was significantly correlated with the LIs of cell cycle regulators such as Ki-67, cdk2, cyclin A, cyclin D1, and cyclin E. We have demonstrated that these cell cycle regulators were positively correlated with histological grade of endometrial adenocarcinoma (Watanabe et al. 2003). It has also been reported that the high expression of cell cycle regulators occurred in poorly differentiated cancers (Sherr 1996; Weng et al. 2001). Therefore, it has been suggested that PTEN protein is expressed as a negative feedback response to control cellular overgrowth (Campbell et al. 2001; Kato et al. 1998).

PTEN expression was not significantly associated with clinicopathological parameters that we examined. However, as it was correlated with cell cycle regulators indicating higher proliferative activity, it will be necessary to follow these patients for a longer period to evaluate PTEN expression as a prognostic factor.

In the present study, PTEN expression was decreased in well-differentiated adenocarcinoma and wild type p53, high ER, and PR groups. It is known that p53 mutation is a late event in endometrial carcinogenesis (Kohler et al. 1992) and expression of both ER and PR is decreased or abolished in poorly differentiated endometrial cancer (Ohtani et al. 1999). This may indicate that decreased PTEN expression is involved in the early stage of carcinogenesis of the endometrium. PTEN expression was high in poorly differentiated cancers. This suggests that PTEN protein may have been induced to inhibit the aggressive growth of the poorly differentiated carcinomas, whereas in well-differentiated cancers PTEN may have been expressed at a low level. It is likely that in poorly differentiated cancers, the mutation of more critical genes than the PTEN gene such as the p53 gene are involved in the acquisition of more aggressive malignancy.

Acknowledgments This work was supported by grants-in-aid for the Project Research of Graduate School of Medical Sciences, Kitasato University (Grants 2005 and 4007) and for Scientific Research from the Ministry of Education, Culture, Sports, Sciences, and Technology (Grants 12670176 and 12671627), Japan.

References

Bussaglia E, DEL Rio E, Matias-Guiu X, Prat J (2000) PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 31:312–317

Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α. J Biol Chem 276:9817–9824

de la Cuesta RS, Eichhorn JH, Rice LW, Fuller Jr AF, Nikrui N, Goff BA (1996) Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 60:238–244

Ellenson LH (2000) The molecular biology of endometrial tumorigenesis: does it have a message? Int J Gynecol Pathol 19:310–313

Fujimoto J, Hirose R, Sakaguchi H, Tamaya T (1998) Estrogen dependency in uterine endometrial cancers. Oncology 55:53–59

Fujisawa T, Watanabe J, Akaboshi M, Ohno E, Kuramoto H (2001) Immunohistochemical study on VEGF expression in endometrial carcinoma – comparison with p53 expression, angiogenesis, and tumor histologic grade. J Cancer Res Clin Oncol 127:668–674

Gimm O, Perren A, Weng L-P, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, Komminoth P, Dralle H, Eng C (2000) Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156:1693–1700

Girl D, Ittmann M (1999) Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 30:419–424

Gu J, Tamura M, Yamada KM (1998) Tumor supressor PTEN inhibits integrin-and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 143:1375–1383

Hata H, Hamano M, Watanabe J, Kuramoto H (1998) Role of estrogen and estrogen-related growth factor in the mechanism of hormone dependency of endometrial carcinoma cells. Oncology 55:35–44

Hinoda Y, Idogawa M, Imai K (1998) Involvement of protein tyrosine phosphatases in cancer development. Protein Nucleic Acid Enzyme 43:1186–1192

Kato N, Watanabe J, Jobo T, Nishimura Y, Fujisawa T, Kamata Y, Kuramoto H, (2003) Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. J Cancer Res Clin Oncol 129:222–226

Kato S, Kitamoto T, Masuhiro Y, Yanagisawa J (1998) Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology 55:5–10

Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr, Marks J (1992) Overexpression and mutation of p53 in enometrial carcinoma. Cancer Res 52:1622–1627

Kurose K, Bando K, Fukino K, Sugisaki Y, Araki T, Emi M, (1998) Somatic mutations of the PTEN/MMAC1 gene in fifteen Japanese endometrial cancers: evidence for in activation of both alleles. Jpn J Cancer Res 89:842–848

Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T, Kuramoto H (2002) Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol 128:307–312

Levine RL, Cargile CB, Blazes MS, Rees Bv, Kurman RJ, Ellenson LH (1998) PTEN mutations and microsatellite instability in complex atypical hyperplasia, a Precursor lesion to uterine endometorioid carcinoma. Cancer Res 58:3254–3258

Maehama T, Dixon JE (2000) Function of PTEN as a phospholipid phosphatase. Cell Technol 19:751–753

Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, Berchuck A, Futreal PA (1998) Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 58:2500–2503

Mochizuki Y (1999) Tumor suppressor gene PTEN/MMAC1 is lipid phosphatase. Exp Med 17:1195–1199

Mutter GL (2000a) Histopathology of genetically defined endometrial precancers. Int J Gynecol Pathol 19:301–309

Mutter GL, Lin M-C, Fitzgerald JT, Kum JB, Baak JPA, Lee JA, Weng L-P, Eng C (2000b) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92:924–931

Mutter GL, Lin M-C, Fitzgerald JT, Kum JB, Eng C (2000c) Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 85:2334-2338

Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095–2097

Ohkawara S, Jobo T, Sato R, Kuramoto H (2000) Comparison of endometrial carcinoma coexisting with and without endometrial hyperplasia. Eur J Gynaec Oncol 6:573–577

Ohtani K, Sakamoto H, Satoh K (1999) Molecular pathogenesis of endometrial hyperplasia and adenocarcinoma. Nihon Univ J Med 41:181–193

Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874–879

Parsons R (1998) Phosphatases and tumorigenesis. Curr Opin Oncol 10:88–91

Perren A, Weng L-P, Boag AH, Ziebold U, Thakore K, Dahia PLM, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253–1260

Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong Y-K, Yung WKA, Steck PA (1999) Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59:1820–1824

Sherman ME (2000) Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13:295–308

Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677

Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 15:356–362

Tamura M, Gu J, Yamada KM (1998a) Tumor suppressor PTEN: a negative regulator of cell adhesions via integrins. Exp Med 16:2211–2213

Tamura M, Gu J, Matsumoto K, Aota S, Persons R, Yamada KM (1998b) Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280:1614–1617

Tamura M, Gu J, Takino T, Yamada KM, (1999) Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and $p130^{cas}$. Cancer Res 59:442–449

Uchida T, Wada C, Shitara T, Egawa S, Koshiba K (1993) Infrequent involvement of p53 gene mutations in the tumorigenesis of Japanese prostate cancer. Br J Cancer 68:751–755

Watanabe J, Sato H, Kanai T, Kamata, Y, Jobo T, Hata H, Fujisawa T, Ohno E, Kuramoto H (2002) Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus — correlation with proliferation and clinicopathological parameters. Br J Cancer 87:81–85

Watanabe J, Kamata Y, Kanai T, Seo N, Fujisawa T, Nishimura Y, Hamano M, Jobo T, Kuramoto H (2003) Expression of cell cycle regulators in endometrial adenocarcinoma. Kuramoto H, Nishida M (eds) Cell and molecular biology of endometrial carcinoma. Springer, Tokyo, pp 93–106

Weng LP, Brown JL, Eng C (2001) PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 10:599–604

特　集　婦人科癌化学療法　新しい展開

子宮頸癌に対する手術前化学療法(NAC)は予後改善に有効か？

Dose neoadjuvant chemotherapy followed by surgery give the impact on survival of advanced cervical cancer patients?

山口　聡 YAMAGUCHI Satoshi
小島　淳美 KOJIMA Atsumi
安田進太郎 YASUDA Shintaro
田中　達也 TANAKA Tatsuya
浅原　彩子 ASAHARA Ayako
竹森　正幸 TAKEMORI Masayuki
西村隆一郎 NISHIMURA Ryuichiro

兵庫県立成人病センター婦人科

Friedlanderら[1]により子宮頸癌の局所進行例に対して主治療たる手術や放射線治療に先行した形で行う化学療法 neoadjuvant chemotherapy (NAC) が導入されて20年が経とうとしている．現在までに，放射線治療に先立って行われるNACに治療的意義が乏しいことは，randomized study を含めた多くの報告のほぼ一致した見解となっている．一方，手術に先立って行われる「術前NAC」は原発病巣に対して70%をこえる高い奏効率を示し，手術適応例を増加させることができるだけでなく，リンパ節転移などの微小転移巣に対してもある程度の効果が期待できる．しかし，これがはたして患者の長期予後を向上させているのかについての明確な答えは得られてはいない．その原因の一つとして，NACがsurgical stagingの前に行われるために，「どのような病期の，どのような病態をNACで治療しているのか？」という常に投げかけられる疑問がその評価を複雑にしているためと思われる．本稿では手術を前提として行われる術前NACをめぐる最近の動向とその予後向上への意義についてレビューする．

Key Words　子宮頸癌，手術前化学療法（NAC），化学療法の奏効率，予後

NACに用いられるレジメンと奏効率

シスプラチンをkey drugとして，ほかのいくつかの薬剤と組み合わせた併用療法が多く用いられている[2][12]（表1）[13]．ほとんどのレジメンにより70%以上の高い一次奏効率が得られており，子宮頸癌が化学療法に感受性の高い固形癌であることをあらためて認識させられる．このような高い一次効果に永続性はないとしても，再発例に対する化学療法の奏効率がたかだか30%に過ぎないことを考えると，初回治療として有効性の高い化学療法を用い，手術へと導入する治療過程は集学的治療の観点からも魅力的である．代表的なNACレジメンであるBOMP療法[14]のプロトコールを表2に示した．最近では，後述するようにpaclitaxel，irinotecan，gemcitabineなども導入されつつあり，やはり高い奏効率が示されている．

NACの投与法と期間

NACの薬剤投与ルートとして，静脈内投与（静注）と動脈内投与（動注）とが行われている．動注は薬剤の腫瘍内濃度を上げて，しかも副作用を軽減できるとされるが[15]，手技が煩雑である．欧米では静注が主流であり，動注を主流としてきた日本においても最近は静注が用いられるようになってきた．

NACの投与方法はweeklyから21日周期までさまざまで，その期間も1ヵ月間の短期から3ヵ月

0558-471X/04/¥50/ 頁 /JCLS

表1　進行子宮頸癌に対するシスプラチンをkey drugとした術前NACの有効性（Gadducci A, et al, 2001[3]より改変）

著者	文献	患者数	Chemotherapy regimen	奏効率	CR率
Dottino	2	28	CDDP + VCR + MIT + BLM	100%	35%
Leone	3	56	CDDP + IFO	54%	7%
Benedetti-Panicl	4	75	CDDP + BLM + MTX	83%	15%
Benedetti-Panici	5	26	CDDP + BLM	88%	19%
Bolis	6	79	CDDP + IFO	69.6%	5.1%
Marth	7	15	CDDP + 5 − FU	93%	27%
Sugiyama	8	23	CDDP + CTP −11	78%	13%
Lai	9	59	CDDP + VCR + BLM	81.4%	18.6%
Serur	10	20	CDDP + MTX + BLM or CDDP + VCR + BLM	90%	10%
Colombo	11	100	CDDP + VCR + BLM	96%	15%
Pignata	12	27	CDDP + VNL	81.5%	25.9%

CDDP, cisplatin ; VCR, vincristine ; MIT, mitomycin-C ; BLM, bleomycin ; IFO, ifosfamide ; MTX, methotrexate ; EPI, epirubicin ; CLB, chlorambucil ; 5-FU, 5-fluorouracil ; CTP-11, irinotecan ; VNL, vinorelbin.
Studies assessing neodjuvant chemotherapy before surgery.

表2　BOMP療法

	day	1	2	3	4	5
BLM	(7mg/m²)	↓	↓	↓	↓	↓
VCR	(0.7mg/m²)					↓
MMC	(7mg/m²)					↓
CDDP	(50mg/m²)					↓

BLM：ブレオマイシン　VCR：ビンクリスチン
MMC：マイトマイシンC　CDDP：シスプラチン
上記療法を3～4週ごとに施行

間投与まで行われ，標準的プロトコールはない．しかし，NACの施行期間はその意義を何に求めるかに関わる重要な問題である．NACには大きく二つの臨床的意義が期待されている．一つは，手術適応を目指した局所的な原発病巣の縮小効果であり，今一つはリンパ節転移などの微小転移巣への全身的効果である．局所的効果を第一義的に考えるなら，手術可能な腫瘍縮小効果が得られ次第に化学療法を打ち切るべきであるが，あわせて全身的効果をも期待するのなら，CRを目指して長期に行われるべきであろう．リンパ節転移などの微小病巣への効果は化学療法のサイクル数との相関が推定されているからである[16]．

しかし，NACが主治療たる手術への導入療法である以上，これが有効でない場合には手術療法への早急な切り替えが必要であるし，放射線療法への移行も早い方がよい．すなわち，NACレジメンとしては原発局所に対する奏効率が高く，しかも効果の発現が迅速であることが望まれる．NACに関する先駆的報告を行っているSardiら[17]が“quick VBP”と名づけた短期NACはその代表的レジメンといえる．そのプロトコールはCDDP＋vincristine (VCR)＋bleomycin (BLM)を10日間隔で3コース施行するものである（表3）．ほかの短期NACとしては，CDDP (50mg/m², day1)＋VCR (1mg/m², day1)＋BLM (25mg/m², day1) をweeklyで3コース施行する方法[18]などが報告されている．いずれの場合にも，NAC期間（約30～40日間）の終了後2～3週間以内に手術療法が施行されている．

われわれもirinotecan (CPT-11)＋mitomycin C (MMC) による短期NAC[19]（表4）を試みている．

表3 Quick VBP 療法

		day	1	2	3	
VCR	(1 mg/m²)		↓			15分
BLM	(25mg/m²)		↓	↓	↓	6時間
CDDP	(50mg/m²)		↓			15分

VCR：ビンクリスチン　BLM：ブレオマイシン
CDDP：シスプラチン
上記療法を10日間隔で3コース施行

表4 CPT-11+MMC 療法

			1コース				2コース		
		day	1	8	15		29	36	43
CPT-11	(100mg/m²)		↓	↓	↓	休薬	↓	↓	↓
MMC	(10mg/m²)								↓

CPT-11：イリノテカン　MMC：マイトマイシンC
上記療法を4週ごとに施行

このレジメンを短期術前NACに導入した理由は，

①効果発現が迅速で，とくにNACではわずか1コース/1ヵ月で65%の高い奏効率が得られる，

②腎不全をきたした進行子宮頸癌患者にも適応できる，

③手術を待つ患者の精神的QOLのため，

などである．しかし，子宮頸癌に対するkey drugであるCDDPを含まないことから初回治療としてのNACレジメンとしては問題が残り，今後の検討が待たれる．

■■2 術前NACが長期予後に与える影響を検討したnon-randomized study

Serurら[20]によるコホート研究では，頸部扁平上皮癌stage Ⅰb2を対象に，NAC＋根治術群（20人）と根治術単独群（32人）が比較された．NACはCDDP＋BLM＋MTXあるいはVBP療法を用いた．NACの奏効率は90%で，腫瘍径の大きい症例がNAC群に多く含まれていたにもかかわらず，5年生存率はNAC群80%，根治術群69%で有意差があったと報告している．Benedetti-Paniciら[21]は128人の局所進行した頸部扁平上皮癌に対してNAC＋根治術を行った結果，10年生存率はstage Ⅰb2～Ⅱa bulky：91%，Ⅱb：80%，Ⅲ：34.5%であり，標準的治療法を行った群よりも予後良好であった．Hwangら[22]は80人の腫瘍径4 cm以上の頸癌stage Ⅰb～Ⅱbに対してNAC（BVP療法）＋根治術＋RTを施行した結果，5年，10年無病生存率はそれぞれ82%，79.4%と良好な予後であったと報告している．

以上の論文をはじめ多くのnon-randomized studyがいずれも術前NACが予後向上をもたらす可能性を示唆してはいるが，どの論文でも最後の文章はいつも「この結果は大規模randomized studyにより裏づけられる必要がある」と結ばれている．

■■3 術前NACに関するrandomized study

NACの有効性を評価したrandomized studyはきわめて少ない．アルゼンチンのSardiら[23]は，309人の頸部扁平上皮癌stage Ⅱbを次の4群に分けてrandomized studyを行った．①放射線治療（RT）群（体外50Gy＋腔内照射），②根治術＋RT群，③NAC（quick VBPx3コース）＋RT群，④NAC＋根治術群．その結果，84ヵ月の平均観察期間後の生存率は，①群48%，②群41%，③群：54%，④群65%であった．NACを含んだ③④群と他群との間に有意差はなかったが，④群と②群の間と④群と①群の間には有意差があった．手術完遂率は④群80%，②群56%であった．結論として，NACにより予後は向上し，手術時のリスク因子である傍結合織浸潤，脈管侵襲，リンパ節転移などを減少させることができるとした．

Changら[24]も頸部扁平上皮癌stage Ⅰb2，Ⅱaを対象に，前述のSardiら[17]とまったく同様のNAC（quick VBP）を3コースの後に根治術を行ったNAC群68例とRT単独群52例との間でrandomized studyを行った．NAC後の手術でリンパ節転移などのリスク因子が確認された症例（28%）のみが補助放射線療法を受けた．その結果，中央値39ヵ月の観察期間で，2年生存率はNAC群81%とRT群84%，5年生存率はNAC群70%とRT群61%で，ともに有意差を認めなかった．

Benedetti-Panici ら[25]によるrandomized studyは頸部扁平上皮癌stage Ⅰb2～Ⅲに対してCDDPをベースとしたNACの後に根治術を行ったNAC群（160名）と，体外照射と腔内照射を行ったRT群（143名）を比較した第3相試験である．NACのレジメンは一定したものではなく，総投与量が240mg/m²以上のCDDPを含んだ多剤併用療法であることを必要条件とした．術後のリスク因子に対する補助療法の（化学療法，RT，無治療など）の選択は主治医のポリシーに委ねられた．その結果，全体の5年生存率はNAC群56.5%とRT群44.4%で有意差があった．また，臨床期別の5年生存率で見ると，stage Ⅰb2～ⅡaではNAC群68.9%とRT群50.7%で有意差があったが，stage ⅡbではNAC群58.6%とRT群56.5%で有意差なし，stage Ⅲでもそれぞれ NAC群41.6%とRT群36.7%で有意差なしであった．

Napolitano ら[26]は頸部扁平上皮癌stage Ⅰb～Ⅲbに対して，NAC（VBP×3コース）＋根治術群102人と根治術単独群（C群）64人の間でのrandomized studyを行った．術後の病理学的リスク因子があった場合には放射線治療が追加されている．その結果，5年生存率は，stage Ⅰb～ⅡaではNAC群78.6%とC群：73.2%で有意差なし，stage ⅡbでもNAC群68.7%とC群64.3%で有意差なしであったが，5年無病生存率で見ると，stage Ⅰb～ⅡaがNAC群77.1%とC群64.3%で有意差あったが，stage ⅡbではNAC群56.2%とC群57.1%で有意差はなかった．結論はNACにより多くの患者が手術可能となりその予後を向上させたとした．

■■■ 腫瘍サイズはNACの効果に影響するか？

以上のrandomized studyでは，いずれも80%を超えるNACの高い一次奏効率が得られてはいる．しかし5年生存率では，NAC＋根治術群がRT単独群や根治術＋RT群に比べてやや優れている傾向にはあるものの，明らかな有意差が示されているわけではない．ここで興味深いことは，Sardi ら[23]が腫瘍サイズの大きい進行例ほどNAC＋根治術の有効性が高いとしているのに対して，Benedetti-Panici ら[25]と Napolitano ら[26]は腫瘍サイズの小さい早期例に対するほど有効性が高い，と相反する結果となっていることである．最近のHuang らの報告[27]でも5cm以上の腫瘍サイズは術前NAC療法のリスク因子であるとしている．Sardi ら[23]だけがNAC＋根治術群の全症例に対して補助放射線療法を行っている点がその原因となっているかは判然としない．はたしてNACがどのような臨床進行期や腫瘍サイズの頸癌に対してより有効であるのかは最も重要な今後の検討課題である．

■■■ NAC後の縮小手術の是非は？

NACにより著明な腫瘍縮小効果が得られた（down staging）場合には，手術は完遂度を増し，局所制御と根治性を高めることができることには十分なコンセンサスが得られている．すなわち，NACによりⅢb期がⅡb期とdown stageして広範子宮全摘術が可能となったり，Ⅱb期がⅠa～Ⅰb期となって準広範術式で切除可能となることが示されている[28]．しかし，現時点でのNACの主たる目的は，手術への適応例を増加させることや，手術の根治性を高めることにあり，縮小手術を可能とすることにはないと思われる．何故なら，NACのリスク因子への影響は広範子宮全摘術を行ってはじめて確認できるからである．とくにリンパ郭清術に関しては，NACがどの程度までリンパ節転移巣を消滅させるかが分からない以上，リンパ節郭清を省略できるというエビデンスは得られない．

■■■ NACはリンパ節転移を減少させるか？

最近の画像診断技術の進歩をもってしても，治療前にリンパ節転移の有無を正確に評価することは困難であり，生検を行わない限り微小転移巣の判定はできない．さらに，化学療法により消失したリンパ節転移巣を術後の病理所見で証明するこ

とも容易ではない．したがって，NACがリンパ節転移巣に与える影響についての客観的評価は難しいが，NACが骨盤内リンパ節転移の陽性率を減少させたとする多くの報告がある．それらをまとめると，NAC後の骨盤内リンパ節郭清により確認された転移陽性率は，Ⅰb2－Ⅱb期10～25%，Ⅲb期30～50%で，NAC前のそれぞれの臨床期から推定される陽性率よりも低いと報告されている[29)～32)]．

腫瘍のリンパ節への転移には，臨床期，原発巣の腫瘍サイズ，腫瘍の分化度などの関与が指摘されているが，NAC後においてもリンパ節転移の陽性率は治療前の腫瘍サイズと相関することが報告されている．Giaroliら[33)]は，頸部扁平上皮癌（stage Ⅰb bulky～Ⅲ）に対して，NAC（modified VBP）を行った後の骨盤内リンパ節転移の陽性率を調べた．その結果，リンパ節転移陽性率は腫瘍径が3cmを下回る症例で9%，3～4cmで10%，4～5cmでは25%であった．一方，5cmを上回る症例では60%の高い陽性率であったが，NACにより3cmとなった場合には14%に低下した．また，NACによりCRとなった56例中ではリンパ節転移陽性はわずか1例のみであったのに対して，stable diseaseであった36人中24人（66.7%）が陽性であったことから，NAC後の手術におけるリンパ節転移の陽性率や個数は，NAC前の腫瘍サイズに比べ化学療法に対する感受性に依存する可能性がより高いことを示唆した．また，予後的にもリンパ節転移が陰性であった場合の2年無病生存率は89.2%であったのに対して，1－2個では約70%，3個以上ではわずか25%と大きな有意差があった．以上の結果から，NAC後に残存腫瘍径が2cm以下になり，リンパ節転移陰性かつ傍結合織陰性のものは手術により最良の予後が得られるが，残存腫瘍径2cm以上でリンパ節転移が陽性であれば傍結合織浸潤はどうあれ，きわめて予後不良であると結論づけた．

以上のことから，NACがどの程度のリンパ節転移を消滅させているか，またそのことが長期予後の改善に寄与しているかについては具体的に示されてはいないものの，大きなリスク因子であるリンパ節転移の陽性率をNACが減少させていることが事実なら，十分に意義深いことと思われる．しかし，このことはNACがより完全なリンパ節郭清を可能にするということであり，これを省略できることを意味せず，予後の推定や向上のために必要な手術操作であることに変わりはない．

■■ NACを先行させた手術後の補助療法は必要か？

手術後の病理検索により，傍結合織浸潤，高度の間質浸潤や脈管侵襲，切除断端陽性，リンパ節転移などのリスク因子が認められれば，NACの有無によらず補助療法としての放射線療法あるいは化学療法の追加が通常行われている．しかし，問題はNAC前には存在したと推定されるリスク因子が手術後には確認されなかった場合である．つまり，術前NACによりリスク因子が消失したと考えられる場合の補助療法をどうするかは難しい判断である．Sardiら[17)]のプロトコールでは，術後の病理所見がどうあろうと全例に対して放射線療法が追加されている．一方，Napolitanoら[26)]のプロトコールでは，リスク因子の認められた症例に対してのみ放射線療法が施行されている．予後的には，前者の方が良好な生存率を報告しているが，過剰治療の可能性も危惧される．また，NAC奏効例に対しては，術後に同じ化学療法を追加する試み[34)]も報告されている．

現時点では，NAC前の進行期に対応して術後の補助療法が行われることが標準的であり，ほとんどの場合で放射線治療が選択されている．また，これに化学療法を併用するか否かは今後の検討課題である．

■■ 頸部腺癌に対する術前NAC

前述してきたNACの成績のほとんどが頸部扁平上皮癌に対するものであり，頸部腺癌に対する術前NACに関する報告は少ない．頸部腺癌の予後は不良であることから，化学療法が期待されて

いるが，NACとしての奏効率は扁平上皮癌に比べて同等か低いことが報告されている．Paniciら[35]は42例の類部腺癌stage Ⅰb2～Ⅲに対してNACを施行し，79%（33例）の奏効率（CR7%）を得た．33例中29例で根治的手術が可能となり，術後の病理所見ではCR7%，PR57%で，骨盤内リンパ転移率は15%であった．その結果，NAC奏効例の5年生存率は84%と扁平上皮癌の場合と同程度に良好であった．Zanettaら[36]は21人の進行類部腺癌に対して，CDDP（50mg/m², weekly）＋epirubicin（70mg/m², every 3 weeks）を施行し，奏効率67%（CR19%）であった．82%が手術を受けたが，病理学的CRはなかった．Iwasakaら[37]は16例の類部腺癌stage IB-Ⅳに対して，CDDP＋MMC＋etoposideによるNACをおこなったが，50%の奏効率（CR19%）であったと報告している．

ほかの報告[38]を含め，類部腺癌に対する現行のNACには扁平上皮癌に対するほどの有効性はないというのが現時点での一般的見解であると思われる．予後も不良であることから化学療法に過大な期待をかけずできるだけ迅速な手術が望ましいと考えられる．

■■ 日本におけるNACの多施設共同研究

本邦でも，婦人科がん化学療法共同研究会（JGOG）において1991年から1997年まで類部扁平上皮癌stage Ⅱに対して，術前NAC群（34例）と手術単独群（22例）の間で封筒法によるpilot studyが行われた．NAC群ではBOMP療法2コースの後，広範子宮全摘術が施行された．また，両群ともに病理学的リスク因子陽性の症例に対しては放射線治療が追加されている．その結果，NACの奏効率は61%（CR9%）であり，間質浸潤と傍結合織浸潤はNAC群で有意に低率であったが，リンパ節転移率には有意差は認められなかった．ところが5年生存率を見ると，手術群の90%に対してNAC群は67%と有意に低率となった．このように期待を裏切る結果となった理由として，症例割りつけを封筒法としたために，より重篤な症例が主治医により恣意的にNAC群に割りつけられた可能性が高い，とはいえ，この術前NAC療法に大きな予後改善は望めぬと判断され，臨床試験は中止された．

現在，日本臨床腫瘍研究グループ（JCOG）により，類部扁平上皮癌stage Ⅰ（bulky）/stage Ⅱに対して，術前NAC（BOMP）群と根治術群の間でrandomized studyが進行中である．両群ともに術後補助療法として放射線療法が追加されるプロトコールである．世界でも数少ないNACのrandomized studyであり，多くの症例登録が期待される．

■■ NACに関する米国GOGトライアル

米国GOGではNACに関するrandomized studyは行われていないが，1995年にpilot studyとして，類部扁平上皮癌stage Ib bulkyに対して術前NAC（CDDP＋VCR）3コースを行って82%の高い奏効率を発表した[39]．ところが，米国では局所進行類癌に対しては放射線療法が主たる治療法となっているうえに，おりしも公表されたconcurrent chemoradiationの良好な成績から，これがNCIアナウンスメントにより推奨されるに及んで，術前NACに関する臨床試験は中断されたままとなっている．

■■ 新しいNACレジメン

最近，タキサン類を類癌に対する術前NACに導入し，高い奏効率が示されている．Zanettaら[40]らは，CDDP（50mg/m², day1）＋ifosfamide（5g/m², day1）＋paclitaxel（175mg/m², day1）からなるNAC（every 21days, 3cycle）を38人の類部扁平上皮癌stage Ⅰb2～Ⅳaに施行し，奏効率84%（CR29%）が得られている．さらに根治術を施行した結果，16%が病理学的CR，18%に微小浸潤癌の残存と，高い病理学的効果が確認された．